News and Trends 20 Dec 2018 Personalized Immunotherapy for Brain Cancer Succeeds in Clinical Trials A European trial has proved the feasibility and efficacy of treating cancer with a personalized immunotherapy tailored to each patient. The phase I/II trial, run across six European centers, tested a combination of two personalized vaccines in patients with glioblastoma, an aggressive form of brain cancer. The first vaccine was designed to immunize the patients […] December 20, 2018 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 20 Dec 2018 Cambridge Company Raises €20M for Potential First in Lung Disease Morphogen-IX, based in Cambridge, has raised €20.4M (£18.4M) to fund a new type of treatments for pulmonary arterial hypertension. The Series B financing will go towards the preclinical development of the company’s lead candidate, which has the potential to become the first to treat the condition rather than just addressing the symptoms. People with pulmonary […] December 20, 2018 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 19 Dec 2018 Italian Biotech Raises Big Series A for ‘Gene Therapy 2.0’ Altheia Science, based in Milan, has raised €17M to fund the development of gene therapies for autoimmune diseases with the remarkable potential to be curative. “The success of our fundraising campaign is unprecedented over a Series A in Italy,” said Paolo Rizzardi, co-founder and CEO of Altheia. The funds will go towards taking the company’s […] December 19, 2018 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 19 Dec 2018 Could We Use CRISPR to Light up Future Christmas Trees? Scientists in the UK have proposed a way to make bioluminescent Christmas trees using the gene editing tool CRISPR-Cas9. CRISPR-Cas9 is a revolutionary gene editing tool that makes it easier to edit the genome. For this reason, it is now a standard tool in research and development centers worldwide, and companies such as the German chemical […] December 19, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 18 Dec 2018 Gut Bacteria Could Combat Obesity and Depression A five-year microbiome project, funded by the EU, has linked the presence of specific strains of gut bacteria to protection from obesity, glucose intolerance, and even depression. The project, called MyNewGut, found evidence that specific strains of bacteria can contribute to obesity in people on high-fat or high-sugar diets. Research led by Yolanda Sanz, Professor […] December 18, 2018 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 17 Dec 2018 Novo Nordisk Partners Dutch Biotech to Prevent Cardiovascular Disease Novo Nordisk and the Dutch company Staten Biotechnology will partner to develop a treatment to remove excess fatty molecules called triglycerides from the blood, high levels of which increase a person’s risk for cardiovascular disease. Novo has agreed to pay up to €430M for the worldwide rights to Staten’s candidate drug, as well as the exclusive […] December 17, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 17 Dec 2018 Series B Boosts British Biotech’s Cell Therapy Automation With €22.6M The UK company Synthace has raised €22.6M to develop its software platform to automate and improve the manufacturing process in gene and cell therapy. The round, led by Hong Kong-based investor Horizons Ventures, will help to fund the development of Synthace’s software designed to automate key protocols in the lab. Furthermore, the funding will help […] December 17, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 14 Dec 2018 Cultured Meat Company Offers a Taste of the First Lab-Grown Steak The Israeli company Aleph Farms has shared with the world the first prototype of a beef steak that has been grown in a lab, harming no animal in the process. Although the world’s first lab-grown burger was tasted in 2013, growing a steak had so far remained a challenge. “We are the first company that […] December 14, 2018 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Startup Scout 14 Dec 2018 This Company is Strengthening Muscles in Neuromuscular Disorders NMD Pharma, our pick of this week, is based in Aarhus, Denmark. The company is flexing its muscles to develop a drug that can treat muscle weakness in orphan neuromuscular disorders such as amyotrophic lateral sclerosis and myasthenia gravis. Mission: To develop drugs to counteract muscle weakness in incurable neuromuscular disorders. Neuromuscular disorders come […] December 14, 2018 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 13 Dec 2018 Janssen Recruits Microbiome Company to Fight Inflammatory Bowel Disease The Israeli biotech BiomX has teamed up with Janssen to use its microbiome technology in the treatment of inflammatory bowel diseases such as Crohn’s disease. Janssen aims to use BiomX’s technology to predict which patients with inflammatory bowel diseases will respond best its treatments based on their microbiome. The financial details of the collaboration were […] December 13, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Interview 13 Dec 2018 Making DNA Quantification More Precise Than Ever Technology advances are taking DNA quantification to a whole new level of precision by making it possible to identify single molecules in a sample. Philip talked to Rémi Dangla, CEO and co-founder of Stilla Technologies, to discuss advances and challenges in the field. Founded in 2013, Stilla Technologies is a French company that makes and […] December 13, 2018 - 4 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 12 Dec 2018 Antibody Hitting Tumor Self-Destruct Button Passes Phase I A first-in-class antibody cancer treatment, from the French company Netris Pharma, has shown good safety and anti-tumor effects in a phase I trial in patients with advanced solid tumors. The antibody met the trial’s primary objective of good tolerability in the 19 recruited patients. In addition, the antibody helped to stabilize the disease and shrink […] December 12, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email